Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
Titel:
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
Auteur:
de Wit, R. Wülfing, C. Castellano, D. Kramer, G. Eymard, J.-C. Sternberg, C.N. Fizazi, K. Tombal, B. Bamias, A. Carles, J. Iacovelli, R. Melichar, B. Sverrisdóttir, Á. Theodore, C. Feyerabend, S. Helissey, C. Foster, M.C. Ozatilgan, A. Geffriaud-Ricouard, C. de Bono, J.